A therapy-related point mutation changes the HLA restriction of an HIV-1 Pol epitope from A2 to B57 and enhances its recognition

AIDS

Volumn 19, Issue 9, 2005, Pages 981-984

  Mason, Rosemarie D ^a   Grant, Michael D ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EPITOPE; HLA A2 ANTIGEN; HLA B57 ANTIGEN; LEUCYLARGINYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLTHREONYLPROLYLASPARTYLYSYLYSINE; LYSINE DERIVATIVE; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; T LYMPHOCYTE; WILD TYPE;

EID: 20644467473     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000171415.07034.0d     Document Type: Article

References (10)

1. Korber BTM, Brander C, Haynes BF, Koup R, Kuiken C, Moore JP, et al., editors. HIV molecular immunology. Los Alamos, New Mexico: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2002.
2. Haas C, Hosmalin A, Duntze J, Debre P, Autran B. Dynamics of HIV variants and specific cytotoxic T-cell recognition in non-progressors and progressors. Immunol Lett 1997;57:63-68.
3. Schmitt M, Harrer E, Goldwich A, Bauerle M, Graedner I, Kalden JR, Harrer T. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 2000;14:653-658.
4. Samri A, Haas G, Duntze J, Bouley JM, Calvez V, Katlama C, Autran B. Immunogencity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol 2000;74:9306-9312.
5. Mason RD, Bowmer MI, Howley CM, Gallant M, Myers JCE, Grant MD. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol 2004;172:7212-7219.
6. Haas G, Samri A, Gomard E, Hosmalin A, Duntze J, Bouley JM, et al. Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. AIDS 1998;12:1427-1436.
7. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004;12:119-124.
8. Langlade-Demoyen P, Michel F, Hoffenbach A, Vilmer E, Dadaglio G, Garcia-Pons F, et al. Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes. J Immunol 1988;141:1949-1957.
9. Lalvani A, Dong T, Ogg A, Patham A, Newell H, Hill AV, et al. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. J Immunol Methods 1997;210:65-77.
10. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vezinet F, Perrin L. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998;72:3520-3523.